GB Sciences Inc
GB Sciences, Inc., a plant-based research and biopharmaceutical drug development company. The company offers cannabis inspired medicines and complex therapeutic mixtures for the prescription drug market. Its intellectual property covers a range of medical conditions and programs in pre-clinical animal stage for Parkinson's disease, neuropathic pain, chronic pain, cytokine release syndrome, stress… Read more
GB Sciences Inc (GBLX) - Total Assets
Latest total assets as of June 2025: $94.47K USD
Based on the latest financial reports, GB Sciences Inc (GBLX) holds total assets worth $94.47K USD as of June 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
GB Sciences Inc - Total Assets Trend (2003–2024)
This chart illustrates how GB Sciences Inc’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
GB Sciences Inc - Asset Composition Analysis
Current Asset Composition (March 2024)
GB Sciences Inc's total assets of $94.47K consist of 100.0% current assets and 0.0% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 11.6% |
| Accounts Receivable | $0.00 | 0.0% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2003–2024)
This chart illustrates how GB Sciences Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: GB Sciences Inc's current assets represent 100.0% of total assets in 2024, unchanged from 100.0% in 2003.
- Cash Position: Cash and equivalents constituted 11.6% of total assets in 2024, down from 93.4% in 2003.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2003.
- Asset Diversification: The largest asset category is goodwill at 0.0% of total assets.
GB Sciences Inc Competitors by Total Assets
Key competitors of GB Sciences Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Halozyme Therapeutics Inc
NASDAQ:HALO
|
USA | $2.22 Billion |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $7.59 Billion |
|
ESSA Pharma Inc
NASDAQ:EPIX
|
USA | $110.50 Million |
|
Shenzhen CAU Technology Co Ltd
SHE:000004
|
China | CN¥260.55 Million |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403
|
China | CN¥9.58 Billion |
|
Nanhua Bio Medicine Co Ltd
SHE:000504
|
China | CN¥841.96 Million |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518
|
China | CN¥509.14 Million |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥27.52 Billion |
GB Sciences Inc - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - GB Sciences Inc generates 0.00x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - GB Sciences Inc is currently not profitable relative to its asset base.
GB Sciences Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 0.02 | 0.02 | 0.57 |
| Quick Ratio | 0.02 | 0.02 | 0.45 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $-5.32 Million | $ -4.99 Million | $ -5.38 Million |
GB Sciences Inc - Advanced Valuation Insights
This section examines the relationship between GB Sciences Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1.08 |
| Latest Market Cap to Assets Ratio | 1.16 |
| Asset Growth Rate (YoY) | -70.6% |
| Total Assets | $103.44K |
| Market Capitalization | $120.50K USD |
Valuation Analysis
Above Book Valuation: The market values GB Sciences Inc's assets above their book value (1.16 x), reflecting positive investor sentiment about the company's future prospects.
Significant Asset Reduction: GB Sciences Inc's assets decreased by 70.6% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for GB Sciences Inc (2003–2024)
The table below shows the annual total assets of GB Sciences Inc from 2003 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-03-31 | $103.44K | -70.64% |
| 2023-03-31 | $352.32K | -86.18% |
| 2022-03-31 | $2.55 Million | -76.40% |
| 2021-03-31 | $10.81 Million | -24.71% |
| 2020-03-31 | $14.35 Million | -52.19% |
| 2019-03-31 | $30.02 Million | +24.84% |
| 2018-03-31 | $24.05 Million | +84.90% |
| 2017-03-31 | $13.01 Million | +434.03% |
| 2016-03-31 | $2.44 Million | +67.80% |
| 2015-03-31 | $1.45 Million | +169.80% |
| 2014-03-31 | $537.98K | +8029.10% |
| 2013-03-31 | $6.62K | -84.85% |
| 2012-03-31 | $43.68K | -58.23% |
| 2011-03-31 | $104.57K | -60.79% |
| 2010-03-31 | $266.72K | +5566.45% |
| 2009-03-31 | $4.71K | +514.49% |
| 2008-03-31 | $766.00 | -99.80% |
| 2007-03-31 | $378.70K | +169.81% |
| 2006-03-31 | $140.36K | +155.41% |
| 2005-03-31 | $54.95K | +407.10% |
| 2004-03-31 | $10.84K | -34.47% |
| 2003-03-31 | $16.54K | -- |